Nine new names have been added to Goldman Sach's Healthcare Strategic Assets Basket, which now consists of 24 names where analysts see a greater than 15% chance of M&A in the next 12 months. Goldman sees total 2022 biopharma M&A capacity at $617B, up 20% from 2021.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.